200 related articles for article (PubMed ID: 23792566)
1. Monitor tumor burden with circulating tumor DNA.
Figg WD; Reid J
Cancer Biol Ther; 2013 Aug; 14(8):697-8. PubMed ID: 23792566
[TBL] [Abstract][Full Text] [Related]
2. Analysis of circulating tumor DNA to monitor metastatic breast cancer.
Dawson SJ; Tsui DW; Murtaza M; Biggs H; Rueda OM; Chin SF; Dunning MJ; Gale D; Forshew T; Mahler-Araujo B; Rajan S; Humphray S; Becq J; Halsall D; Wallis M; Bentley D; Caldas C; Rosenfeld N
N Engl J Med; 2013 Mar; 368(13):1199-209. PubMed ID: 23484797
[TBL] [Abstract][Full Text] [Related]
3. The dynamic range of circulating tumor DNA in metastatic breast cancer.
Heidary M; Auer M; Ulz P; Heitzer E; Petru E; Gasch C; Riethdorf S; Mauermann O; Lafer I; Pristauz G; Lax S; Pantel K; Geigl JB; Speicher MR
Breast Cancer Res; 2014 Aug; 16(4):421. PubMed ID: 25107527
[TBL] [Abstract][Full Text] [Related]
4. Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.
Parkinson CA; Gale D; Piskorz AM; Biggs H; Hodgkin C; Addley H; Freeman S; Moyle P; Sala E; Sayal K; Hosking K; Gounaris I; Jimenez-Linan M; Earl HM; Qian W; Rosenfeld N; Brenton JD
PLoS Med; 2016 Dec; 13(12):e1002198. PubMed ID: 27997533
[TBL] [Abstract][Full Text] [Related]
5. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
[TBL] [Abstract][Full Text] [Related]
6. Cell-free circulating tumour DNA as a liquid biopsy in breast cancer.
De Mattos-Arruda L; Caldas C
Mol Oncol; 2016 Mar; 10(3):464-74. PubMed ID: 26776681
[TBL] [Abstract][Full Text] [Related]
7. Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
Chamberlin MD; Wells JD; Shee K; Bean JR; Marotti JD; Wells WA; Trask HW; Kolling FW; Bhatt A; Kaufman PA; Schwartz GN; Gemery JM; McNulty NJ; Tsapakos MJ; Barth RJ; Arrick BA; Gui J; Miller TW
Breast Cancer Res Treat; 2020 Aug; 182(3):665-677. PubMed ID: 32562118
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.
Madic J; Kiialainen A; Bidard FC; Birzele F; Ramey G; Leroy Q; Rio Frio T; Vaucher I; Raynal V; Bernard V; Lermine A; Clausen I; Giroud N; Schmucki R; Milder M; Horn C; Spleiss O; Lantz O; Stern MH; Pierga JY; Weisser M; Lebofsky R
Int J Cancer; 2015 May; 136(9):2158-65. PubMed ID: 25307450
[TBL] [Abstract][Full Text] [Related]
9. Methylation patterns in serum DNA for early identification of disseminated breast cancer.
Widschwendter M; Evans I; Jones A; Ghazali S; Reisel D; Ryan A; Gentry-Maharaj A; Zikan M; Cibula D; Eichner J; Alunni-Fabbroni M; Koch J; Janni WJ; Paprotka T; Wittenberger T; Menon U; Wahl B; Rack B; Lempiäinen H
Genome Med; 2017 Dec; 9(1):115. PubMed ID: 29268762
[TBL] [Abstract][Full Text] [Related]
10. Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer.
Neves RP; Raba K; Schmidt O; Honisch E; Meier-Stiegen F; Behrens B; Möhlendick B; Fehm T; Neubauer H; Klein CA; Polzer B; Sproll C; Fischer JC; Niederacher D; Stoecklein NH
Clin Chem; 2014 Oct; 60(10):1290-7. PubMed ID: 25267515
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
[TBL] [Abstract][Full Text] [Related]
12. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
[TBL] [Abstract][Full Text] [Related]
13. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
14. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.
Mu Z; Benali-Furet N; Uzan G; Znaty A; Ye Z; Paolillo C; Wang C; Austin L; Rossi G; Fortina P; Yang H; Cristofanilli M
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27706044
[TBL] [Abstract][Full Text] [Related]
15. Circulating Plasma Tumor DNA.
Parsons HA; Beaver JA; Park BH
Adv Exp Med Biol; 2016; 882():259-76. PubMed ID: 26987539
[TBL] [Abstract][Full Text] [Related]
16. The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring.
Openshaw MR; Page K; Fernandez-Garcia D; Guttery D; Shaw JA
Expert Rev Mol Diagn; 2016 Jul; 16(7):751-5. PubMed ID: 27144417
[TBL] [Abstract][Full Text] [Related]
17. The feasibility of using mutation detection in ctDNA to assess tumor dynamics.
Yi X; Ma J; Guan Y; Chen R; Yang L; Xia X
Int J Cancer; 2017 Jun; 140(12):2642-2647. PubMed ID: 28124376
[TBL] [Abstract][Full Text] [Related]
18. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
19. Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.
Fackler MJ; Lopez Bujanda Z; Umbricht C; Teo WW; Cho S; Zhang Z; Visvanathan K; Jeter S; Argani P; Wang C; Lyman JP; de Brot M; Ingle JN; Boughey J; McGuire K; King TA; Carey LA; Cope L; Wolff AC; Sukumar S
Cancer Res; 2014 Apr; 74(8):2160-70. PubMed ID: 24737128
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
